2015 Fiscal Year Final Research Report
Clarify of chemo-resistant mechanism in lung cancer targeting to epigenetic aberration
| Project/Area Number |
25462182
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORI Tsutomu 福島県立医科大学, 看護学部, 准教授 (60244373)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OSUGI Jun 福島県立医科大学, 医学部, 博士研究員 (40532528)
HASEGAWA Takeo 福島県立医科大学, 医学部, 助教 (80532530)
GOTOH Mitsukazu 福島県立医科大学, 医学部, 博士研究員 (50162160)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 肺癌 / 分子標的 |
|---|
| Outline of Final Research Achievements |
UHRF family molecules were significantly highly expressed in squamous cell carcinoma as compare with that of adenocarcinoma in lung cancer. Furthermore, these molecules might be prognostic factor and involve to chemo-resistant mechanism. Novel biomarker named FAM83B were identified by our comprehensive gene expression analysis. FAM83B could be a diagnostic and prognostic biomarker in lung squamous cell cancer. Also, FAM83B was involved to cancer proliferation in EGFR wild type lung adenocarcinoma.
|
| Free Research Field |
呼吸器外科
|
